A Phase 4 interventional study of repaglinide and gliclazide in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-07-09.
Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing repaglinide in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. repaglinide · Diabetes Mellitus, Type 2.
Among the 22 studies testing repaglinide in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 3 that started in 2009, is one of 15 in phase 4, and was the 10th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 22 studies testing repaglinide in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
repaglinide: first FDA approval 1997 (PRANDIN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 440 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 101 across the 22 interventional studies. Of the 20 that completed or were terminated, 2 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 117th largest by enrollment of the 428 interventional ones that give a count, is one of 30 that started in 2009, is one of 75 in phase 4, and was the 180th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing repaglinide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood glucose lowering effect and the safety profile of repaglinide given alone compared to gliclazide given alone in Chinese subjects with type 2 diabetes who never have been treated with oral anti-diabetic drugs (OADs). This study also investigates the augment effect of repaglinide on the phases of insulin secretion as a subgroup study.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 440 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 mg repaglinide twice daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 4 mg three times daily
Drug: repaglinide
80 mg gliclazide once daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 160 mg twice daily
Drug: gliclazide
Individually adjusted dose for 16 weeks
Individually adjusted dose for 16 weeks
Change in Glycosylated Haemoglobin (HbA1c)
Time frame: Week 0, week 16
Change in Fasting Plasma Glucose
Time frame: Week 0, week 16
Change in 2-hour Postprandial Plasma Glucose (PPG) Over a Standard Meal
A standard meal contains 100g carbohydrate
Time frame: Week 0, week 16
Percentage of Participants Achieving the Treatment Target of HbA1c Below or Equal to 6.5%
Time frame: Week 16
Change in Fasting Serum Free Fatty Acid (FFA) From Baseline
Time frame: Week 0, week 16
Change in 2-hour Postprandial Serum Free Fatty Acid (FFA) Over a Standard Meal
Time frame: Week 0, week 16
Change in AUC0-180 of Serum Insulin Concentration of IVGTT (Intravenous Glucose Tolerance Test)
Time frame: Over the course of three hours at Week 0 and Week 16
Change in AUC0-180 of Plasma Glucose Concentration of IVGTT
Time frame: Over the course of three hours at Week 0 and Week 16
Number of All Treatment Emergent Hypoglycaemic Episodes
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of trial product and no later than the last day of the trial product.
Time frame: Weeks 0-16
Cholesterol
The number of participants having a change in cholesterol from "normal" to "abnormal". "Abnormal" means a value of blood cholesterol is out of the normal range.
Time frame: Week 0, week 16
Change in Body Weight
Time frame: Week 0, week 16
The trial was conducted at 23 sites in China.
| Milestone | Repaglinide | Gliclazide |
|---|---|---|
| Started | 218 | 222 |
| Exposed to trial drug | 217 | 218 |
| Completed | 196 | 194 |
| Not completed | 22 | 28 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Protocol violation | 7 | 6 |
| Withdrew: Unclassified | 12 | 20 |
| percentage (%) of total haemoglobin | Repaglinide | Gliclazide |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) | -0.857 ± 0.051 | -0.871 ± 0.051 |
| mmol/L | Repaglinide | Gliclazide |
|---|---|---|
| Change in Fasting Plasma Glucose | -1.409 ± 0.104 | -1.667 ± 0.102 |
A standard meal contains 100g carbohydrate
| mmol/L | Repaglinide | Gliclazide |
|---|---|---|
| Change in 2-hour Postprandial Plasma Glucose (PPG) Over a Standard Meal | -0.596 ± 0.215 | -0.699 ± 0.211 |
| percentage of participants | Repaglinide | Gliclazide |
|---|---|---|
| Percentage of Participants Achieving the Treatment Target of HbA1c Below or Equal to 6.5% | 62 | 59 |
| mmol/L | Repaglinide | Gliclazide |
|---|---|---|
| Change in Fasting Serum Free Fatty Acid (FFA) From Baseline | -0.012 ± 0.014 | -0.02 ± 0.014 |
| mmol/L | Repaglinide | Gliclazide |
|---|---|---|
| Change in 2-hour Postprandial Serum Free Fatty Acid (FFA) Over a Standard Meal | -0.003 ± 0.007 | -0.004 ± 0.007 |
| min*pmol/L | Repaglinide | Gliclazide |
|---|---|---|
| Change in AUC0-180 of Serum Insulin Concentration of IVGTT (Intravenous Glucose Tolerance Test) | 5139.55 ± 8720.80 | 1426.21 ± 5262.15 |
| min*mmol/L | Repaglinide | Gliclazide |
|---|---|---|
| Change in AUC0-180 of Plasma Glucose Concentration of IVGTT | -272.30 ± 290.79 | -348.03 ± 258.86 |
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of trial product and no later than the last day of the trial product.
| episodes | Repaglinide | Gliclazide |
|---|---|---|
| Number of All Treatment Emergent Hypoglycaemic Episodes | 165 | 147 |
The number of participants having a change in cholesterol from "normal" to "abnormal". "Abnormal" means a value of blood cholesterol is out of the normal range.
| participants | Repaglinide | Gliclazide |
|---|---|---|
| Cholesterol | 18 | 11 |
| kg | Repaglinide | Gliclazide |
|---|---|---|
| Change in Body Weight | -0.750 ± 0.218 | -0.511 ± 0.215 |
Collected over The adverse events were collected in a timespan of 16 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Repaglinide | — | 3/216 (1.4%) | 0/216 (0%) |
| Gliclazide | — | 0/219 (0%) | 0/219 (0%) |
| Event | Repaglinide | Gliclazide |
|---|---|---|
| Haemorrhoidal haemorrhageGastrointestinal disorders | 1/216 | 0/219 |
| Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders | 1/216 | 0/219 |
| Gall bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/216 | 0/219 |
| Age, Continuous(years) | Repaglinide | Gliclazide | Total |
|---|---|---|---|
| Mean | 54.1 ± 10.0 | 53.5 ± 9.9 | 53.8 ± 9.9 |
| Sex: Female, Male(Participants) | Repaglinide | Gliclazide | Total |
|---|---|---|---|
| Female | 107 | 95 | 202 |
| Male | 110 | 123 | 233 |
| Ethnicity (NIH/OMB)(Participants) | Repaglinide | Gliclazide | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 217 | 218 | 435 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Repaglinide | Gliclazide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 217 | 218 | 435 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Repaglinide | Gliclazide | Total |
|---|---|---|---|
| China | 217 | 218 | 435 |
| Height(cm) | Repaglinide | Gliclazide | Total |
|---|---|---|---|
| Mean | 163.2 ± 8.9 | 163.9 ± 8.4 | 163.5 ± 8.7 |
| Weight(kg) | Repaglinide | Gliclazide | Total |
|---|---|---|---|
| Mean | 68.7 ± 11.6 | 68.4 ± 11.2 | 68.6 ± 11.4 |
| Body Mass Index (BMI)(kg/m^2) | Repaglinide | Gliclazide | Total |
|---|---|---|---|
| Mean | 25.69 ± 3.00 | 25.37 ± 3.01 | 25.53 ± 3.00 |
1 further baseline measures are reported on the registry.
The record gives a start of Nov 2009, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Repaglinide · Gliclazide